Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players

Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players
Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players
by is licensed under

Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief. Leading specialty pharma companies such as India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Cara Therapeutics, Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), and INSYS Therapeutics, Inc. (NASDAQ: INSY) are tirelessly working to expand combination therapeutics product lines, while Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) developing an opioid alternative drug intended to reduce pain after surgery.

To date, it is estimated that the annual national cost of pain is between $560 billion and $635 billion – more than priority health conditions among the nation. Sadly, the treatment of postoperative pain remains a daunting challenge for health care professionals, leaving patients debilitated in ways that can affect their daily functioning and, in turn, have a significant impact on our nation’s overall productivity. At present, patients face a significant disadvantage when using opioid drugs to treat postoperative and chronic severe pain, and usage thereof can lead to impactful side effects such as nausea, hallucinations, respiratory depression, constipation, and sedation.

Read the full article

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Tags
Cannabis Focus, Cannabis Industry, Health
Thumbnail Photo Credit: by is licensed under